Profile data is unavailable for this security.
About the company
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-19.09m
- Incorporated2020
- Employees21.00
- LocationLantern Pharma Inc1920 MCKINNEY AVENUE, 7TH FLOORDALLAS 75201United StatesUSA
- Phone+1 (972) 277-1136
- Fax+1 (302) 655-5049
- Websitehttps://www.lanternpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics Inc | 1.51m | -45.57m | 28.33m | 57.00 | -- | 0.7678 | -- | 18.73 | -5.84 | -5.84 | 0.1753 | 4.00 | 0.0368 | -- | 31.17 | 26,539.12 | -110.96 | -- | -142.16 | -- | -- | -- | -3,012.26 | -- | -- | -- | 0.0856 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -9.16m | 29.03m | 8.00 | -- | 4.11 | -- | -- | -0.572 | -0.572 | 0.00 | 0.2946 | 0.00 | -- | -- | 0.00 | -135.25 | -- | -180.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -14.40m | 29.61m | 20.00 | -- | 1.85 | -- | -- | -0.9868 | -0.9868 | 0.00 | 0.8654 | 0.00 | -- | -- | 0.00 | -64.98 | -- | -83.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Hcw Biologics Inc | 3.50m | -37.33m | 29.79m | 45.00 | -- | -- | -- | 8.52 | -1.00 | -1.00 | 0.0939 | -0.2636 | 0.1125 | -- | 5.13 | 77,688.45 | -120.09 | -- | -279.71 | -- | 32.41 | -- | -1,067.83 | -- | -- | -93.78 | 4.52 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | 1.16m | 30.12m | 1.00 | 25.98 | 0.9633 | 13.58 | -- | -0.2094 | -0.2094 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | 2.39 | -- | 3.04 | -- | -- | -- | -- | -- | -- | -- | 0.189 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Surrozen Inc | 10.00m | -44.44m | 30.22m | 42.00 | -- | 5.33 | -- | 3.02 | -17.05 | -17.05 | 3.81 | 1.74 | 0.1961 | -- | 1.41 | 238,095.20 | -87.16 | -- | -99.66 | -- | -- | -- | -444.38 | -- | -- | -1.43 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Clene Inc. | 421.00k | -36.02m | 30.40m | 82.00 | -- | -- | -- | 72.22 | -5.58 | -5.58 | 0.0652 | -0.6016 | 0.0092 | 0.7759 | 13.16 | 5,134.15 | -78.31 | -39.43 | -136.18 | -47.32 | 78.62 | -- | -8,556.77 | -5,261.20 | 0.8213 | -10.15 | 1.30 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -563.35k | 31.22m | 6.00 | -- | 4.29 | -- | -- | -0.1931 | -0.1931 | 0.00 | 0.2225 | 0.00 | -- | -- | 0.00 | -2.66 | -144.28 | -3.77 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -19.09m | 31.81m | 21.00 | -- | 1.20 | -- | -- | -1.77 | -1.77 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -48.91 | -28.83 | -52.88 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 31.89m | 22.00 | -- | 0.3482 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -8.82m | 32.21m | -- | -- | 43.15 | -- | -- | -0.2378 | -0.2378 | 0.00 | 0.0206 | 0.00 | -- | -- | -- | -56.73 | -- | -163.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.42m | 163.00 | -- | 0.1589 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.61m | 32.75m | 32.00 | -- | 0.5835 | -- | -- | -1.08 | -1.08 | 0.00 | 5.54 | 0.00 | -- | -- | -- | -16.17 | -31.68 | -16.64 | -33.95 | -- | -- | -- | -56,271.43 | -- | -- | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Passage Bio Inc | 0.00 | -68.80m | 33.11m | 58.00 | -- | 0.4553 | -- | -- | -1.17 | -1.17 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -48.97 | -48.56 | -56.34 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Curis Inc | 10.26m | -45.48m | 34.04m | 48.00 | -- | -- | -- | 3.32 | -7.81 | -7.81 | 1.76 | -1.45 | 0.1549 | -- | 3.52 | 213,729.20 | -68.68 | -37.25 | -94.06 | -41.12 | 98.68 | 96.05 | -443.35 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Lantern Pharma Inc's reporting currency: US Dollar USD
9.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 361.37k | 3.36% |
| CM Management LLCas of 30 Sep 2024 | 185.00k | 1.72% |
| NewEdge Advisors LLCas of 30 Sep 2024 | 137.34k | 1.28% |
| Geode Capital Management LLCas of 30 Sep 2024 | 87.44k | 0.81% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 84.00k | 0.78% |
| Davenport & Co. LLCas of 30 Sep 2024 | 53.81k | 0.50% |
| Redmond Asset Management LLCas of 30 Sep 2024 | 38.92k | 0.36% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 35.87k | 0.33% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 35.57k | 0.33% |
| Two Sigma Investments LPas of 30 Sep 2024 | 34.34k | 0.32% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
